Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
Opdivo (nivolumab)
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor as well as places in New Zealand and Australia. The randomized trial is known as DREAM3R. It wants to figure[…]
Researchers are Developing a Test to Determine Which Mesothelioma Patients Will Benefit From Immunotherapy
Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
The ONCOS-102 Vaccine Was Just Given the Fast-Track Designation
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
Nivolumab Can Help Increase the Survival in Mesothelioma Patients Whose Cancer Has Relapsed
A study in the United Kingdom involving 332 patients who cannot receive surgery (unresectable) found that patients whose mesothelioma has relapsed can be treated with nivolumab safely. Nivolumab is an immunotherapy drug known as Opdivo, which is popular for treating non-small cell lung cancer. Opdivo is promising because it is[…]
Opdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent[…]
Mesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being[…]
Opdivo and Yervoy Combination Could Lengthen Aggressive Mesothelioma Sufferers’ Lives
The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a[…]
Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma
Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]
Nivolumab to Help Treat Mesothelioma
A new study found that the PD-L1 inhibitor nivolumab is effective in mesothelioma. It was tested on patients and showed that it could be a safe and effective treatment for those whose first line treatments have failed. Nivolumab is an immunotherapy drug that helps the immune system fight cancer cells.[…]
